Polarean Imaging enjoys strong market support for its commercialisation plans

0
2
  • Polarean Imaging lands second order from the University of British Columbia
  • Polarean Imaging reveals Oxford research on hyperpolarised xenon MRI scans for long Covid-19
lung

Quick facts: Polarean Imaging PLC

Follow

View company profile

Located in the Research Triangle Park area of North Carolina, Polarean Imaging plc. designs and manufactures equipment for production of hyperpolarized xenon or helium gas.

When used in conjunction with MRI, these gases offer a fundamentally new and non-invasive functional imaging platform. Current investigational uses include identifying early diagnoses of respiratory diseases as well as monitoring progression and therapeutic response. In addition, xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

10 May 2021

() shares jumped 5.4% to 97p in early dealings after the company announced a new order from an existing customer.

The medical imaging technology company said it has received an additional research unit order for a 9820 Xenon Polariser system from the University of British Columbia (UBC). This is the second system installation at UBC, following the original order in November 2019 that was initially installed at BC Children’s Hospital while construction was carried out on its intended original site at St. Paul’s.

As with the original system, this new unit will continue to support UBC’s pulmonary disease research programme using hyper-polarised gas imaging.

“We value our long-standing relationship with UBC, a globally recognised research group, and we are excited that they are adding an additional Polariser system to expand their research into the clinical applications of this emerging and much-needed technology,” said Polarean’s chief executive, Richard Hullihen.

Read more

06 Apr 2021

(), the medical imaging technology company, conditionally raised its target total of GBP2mln through the open offer announced last month.

Combined with the money raised by the share placing and subscription, the company has conditionally raised around GBP27mln, which has been earmarked for the commercialisation of its breakthrough drug-device combination that uses hyper-polarised xenon gas in magnetic resonance imaging (MRI) lung imaging.

Read more

16 Mar 2021

() has announced plans to raise a minimum of GBP20mln via a placing and open offer of new shares.

The cash will be deployed to commercialise its breakthrough drug-device combination that uses hyperpolarised xenon gas in MRI lung imaging.

Read more

28 May 2021

‘s () Richard Hullihen joins Proactive London’s Katie Pilbeam to discuss an article on hyper-polarised xenon.

The Oxford Biomedical Research Centre revealed the research, concerning a study carried out in longer-term lung damage after COVID-19.

This preliminary research determined that hyperpolarised xenon MRI scans had found abnormalities in the lungs of some COVID-19 patients more than three months – and in some cases, nine months – after leaving hospital, when other clinical measurements were normal.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Polarean Imaging reveals Oxford research on hyperpolarised xenon MRI scans…

Polarean Imaging PLC’s (LON:POLX) Richard Hullihen joins Proactive London’s Katie Pilbeam to discuss an article on hyper-polarised xenon.

The Oxford Biomedical Research Centre revealed the research, concerning a study carried out in longer-term lung damage after COVID-19.

This…

7 hours, 31 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here